1. Signaling Pathways
  2. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  3. EGFR

EGFR

EGFR

Epidermal growth factor receptor; ErbB-1; HER1

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-19816A
    Avitinib maleate
    Inhibitor 99.86%
    Avitinib (Abivertinib) maleate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate shows anticancer effects.
    Avitinib maleate
  • HY-137191
    CH7233163
    Inhibitor 99.61%
    CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities.
    CH7233163
  • HY-147941A
    MS9427 TFA
    Degrader 99.01%
    MS9427 TFA is a potent PROTAC EGFR degrader with Kds of 7.1 nM and 4.3 nM for EGFR WT and EGFR L858R, respectively. MS9427 TFA selectively degrades the mutant but not the WT EGFR through both the ubiquitin/proteasome system (UPS) and autophagy/lysosome pathways. MS9427 TFA potently inhibits the proliferation of NSCLC cells. MS9427 TFA can be used for researching anticancer.
    MS9427 TFA
  • HY-16069A
    Tucatinib hemiethanolate
    Inhibitor 99.97%
    Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.
    Tucatinib hemiethanolate
  • HY-20878
    Tyrphostin AG 879
    Inhibitor 99.85%
    Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC50 of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective ErbB2 tyrosine kinase inhibitor with an IC50 of 1 μM, and has at least 500-fold higher selectivity to ErbB2 than EGFR. Tyrphostin AG 879 has anticancer activity.
    Tyrphostin AG 879
  • HY-10325
    CL-387785
    Inhibitor 98.05%
    CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370 pM.
    CL-387785
  • HY-78869
    Mutated EGFR-IN-1
    Inhibitor 99.89%
    Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.
    Mutated EGFR-IN-1
  • HY-141640
    MS154
    Inhibitor 99.42%
    MS154 is a first-in-class E3 ligase cereblon-recruiting EGFR degrader with Kds of 1.8 nM and 3.8 nM for EGFR WT and EGFR L858R mutants. MS154 potently induces the degradation of mutant but not wild-type EGFR in an E3 ligase-dependent manner in cancer cell lines. MS154 potently inhibits cell proliferation in lung cancer cells (Blue: E3 Ligase ligand (HY-103596); Black: linker (HY-W096167); Pink: EGFR ligand (HY-168305)).
    MS154
  • HY-41404
    Piperonylic acid
    99.91%
    Piperonylic acid is a natural molecule bearing a methylenedioxy function that closely mimics the structure of trans-cinnamic acid. Piperonylic Acid is a selective, mechanism-based inactivator of the trans-cinnamate 4-Hydroxylase. Piperonylic acid has anticancer, antioxidant and antibacterial activities.
    Piperonylic acid
  • HY-103443
    HKI-357
    Inhibitor 99.24%
    HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
    HKI-357
  • HY-P99437
    Anbenitamab
    Inhibitor 99.22%
    Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research.
    Anbenitamab
  • HY-P99866
    Duligotuzumab
    Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3).
    Duligotuzumab
  • HY-124813
    PDZ1i
    Inhibitor 99.29%
    PDZ1i is a potent, BBB-penetrated and specific MDA-9/Syntenin inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving FAK and EGFRvIII. PDZ1i reduces MMP secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion.
    PDZ1i
  • HY-N2510
    Myristicin
    Inhibitor 99.89%
    Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc.
    Myristicin
  • HY-155537
    Pruvonertinib
    Inhibitor 99.50%
    YK-029A is an orally active inhibitor of mutant EGFR,targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity,and results tumor regression in EGFRex20ins-driven PDX models.
    Pruvonertinib
  • HY-10261B
    (E/Z)-Afatinib
    Inhibitor 99.98%
    (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells.
    (E/Z)-Afatinib
  • HY-101219
    VEGFR-IN-1
    Inhibitor 98.42%
    VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.
    VEGFR-IN-1
  • HY-13895
    WHI-P154
    Inhibitor 99.39%
    WHI-P154 is a potent EGFR inhibitor, and also modestly blocks JAK3, with IC50s of 4 nM and 1.8 μM, respectively.
    WHI-P154
  • HY-18963
    Lavendustin A
    Inhibitor 98.02%
    Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC50 of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis.
    Lavendustin A
  • HY-N7005
    Clitorin
    Inhibitor 99.45%
    Clitorin is an orally active flavonoid compound that can be isolated from Carica papaya. Clitorin is an inhibitor of EGFR (IC50: 89.58 nM) and aromatase (IC50: 77.41 nM). Clitorin has antioxidant and anti-tumor activities. In the DPPH and ABTS radical scavenging assays, Clitorin has IC50 values of 91.96 ppm and 250.45 ppm, respectively. In addition, Clitorin can regulate lipogenesis and fatty acid oxidation and can be used in the research of non-alcoholic fatty liver disease.
    Clitorin
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

EGFR/ErbB1/HER1

ErbB2/HER2

ErbB3/HER3

ErbB4/HER4

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

EGFR Degraders, Inducers, Inhibitors, Agonists, Antagonists, Activators & Modulators
Product NameEGFR/ErbB1/HER1ErbB2/HER2ErbB3/HER3ErbB4/HER4Purity    
Osimertinib
EGFRL858R, IC50: 12 nM (Enzyme assays)
EGFRL858R/T790M, IC50: 1 nM (Enzyme assays)
   99.96%
Trastuzumab 
HER2
  99.80%
Cetuximab
Soluble EGFR, Kd: 0.201 nM
EGFR, Kd: 0.147 nM (Fixed A431 cells)
   99.70%
Gefitinib
EGFR
   99.95%
Erlotinib
EGFR, IC50: 2 nM (Cell Free Assay)
   99.99%
Afatinib
EGFR, IC50: 0.5 nM
EGFRL858R, IC50: 0.4 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
  99.92%
Lapatinib
EGFR, IC50: 10.2 nM (Cell Free Assay)
ErbB2, IC50: 9.8 nM (Cell Free Assay)
  99.83%
Genistein
EGFR, IC50: 0.6 μM (Cell Assay)
   99.82%
AG490
EGFR
   99.86%
Tucatinib 
HER2
  99.82%
Neratinib
EGFR, IC50: 92 nM
HER2, IC50: 59 nM
  99.94%
Disitamab vedotin 
HER2
  ≥99.0%
Pertuzumab 
HER2
  99.80%
Dacomitinib
EGFR, IC50: 6 nM
ErbB2, IC50: 45.7 nM
 
ErbB4, IC50: 73.7 nM
99.74%
AG-1478
EGFR, IC50: 3 nM
   99.57%
Osimertinib mesylate
EGFRL858R/T790M, IC50: 1 nM
EGFRL858R, IC50: 12 nM
   99.97%
NSC 228155
EGFR
   ≥98.0%
Lazertinib
EGFRT790M
   99.87%
Erlotinib Hydrochloride
EGFR, IC50: 2 nM
   99.94%
Zanidatamab 
HER2
  
Sapitinib
EGFR, IC50: 4 nM
ErbB2, IC50: 3 nM
HER3, IC50: 4 nM
 99.93%
Mobocertinib
EGFR (WT)
EGFR exon 20 insertion
HER2
  99.60%
Almonertinib
EGFRT790M, IC50: 0.37 nM
EGFRL858R/T790M, IC50: 0.29 nM
EGFRdel19 T790M, IC50: 0.21 nM
   99.83%
CUDC-101
EGFR, IC50: 2.4 nM
HER2, IC50: 15.7 nM
  99.05%
Pyrotinib
EGFR, IC50: 13 nM
HER2, IC50: 38 nM
  99.89%
Afatinib dimaleate
EGFR, IC50: 0.5 nM
EGFRL858R, IC50: 0.4 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
  99.74%
Firmonertinib mesylate
EGFR
   99.97%
Icotinib
EGFR, IC50: 5 nM
   99.99%
Gefitinib hydrochloride
EGFR
   99.85%
Chrysophanol
EGFR
   99.77%
Pelitinib
EGFR, IC50: 38.5 nM
   99.13%
Lifirafenib
EGFR, IC50: 29 nM
EGFRL858R/T790M, IC50: 495 nM
   98.01%
Butein
EGFR, IC50: 16 μM (in HepG2 cells)
   99.95%
Daphnetin
EGFR, IC50: 7.67 μM
   99.77%
Mubritinib 
HER2, IC50: 6 nM
  99.91%
Osimertinib dimesylate
EGFRL858R, IC50: 12 nM
EGFRL858R/T790M, IC50: 1 nM
   99.96%
TX1-85-1  
ErbB3, IC50: 23 nM
 98.28%
Canertinib
EGFR, IC50: 7.4 nM
ErbB2, IC50: 9 nM
  99.74%
Olmutinib
EGFRExon 19 deletion, IC50: 9.2 nM (Cell Assay)
EGFRL858R/T790M, IC50: 10 nM (Cell Assay)
   99.88%
Sunvozertinib
EGFR exon 20 insertion, IC50: 20.4 nM
EGFRL858R/T790M, IC50: 1.1 nM
Her2 Exon20 YVMA, IC50: 7.5 nM
  99.71%
Lapatinib ditosylate
EGFR, IC50: 10.8 nM (Cell Free Assay)
ErbB2, IC50: 9.2 nM (Cell Free Assay)
  99.98%
PD153035
EGFR, Ki: 6 pM
EGFR, IC50: 25 pM
   98.83%
Petosemtamab
EGFR, Kd: 0.22 nM
   
AZ-5104
EGFRL858R/T790M, IC50: 1 nM
EGFRL858R, IC50: 1 nM
EGFRL861Q, IC50: 6 nM
EGFR, IC50: 25 nM
  
ErbB4, IC50: 7 nM
99.69%
Zorifertinib
EGFR, IC50: 0.3 nM
EGFRL858R, IC50: 0.2 nM
EGFRExon 19 deletion, IC50: 0.2 nM
   99.37%
Disitamab 
HER2
  98.70%
Gefitinib-based PROTAC 3
EGFR, DC50: 11.7 nM (HCC827(exon 19 del) cells)
EGFR, DC50: 22.3 nM (H3255 (L858R mutantion) cells)
   99.98%
Avitinib
EGFR L858R, IC50: 0.18 nM
EGFRT790M, IC50: 0.18 nM
EGFR (WT), IC50: 7.68 nM
   99.95%
Rociletinib
EGFRL858R/T790M, Ki: 21.5 nM
EGFRT790M, Ki: 303.3 nM
   99.79%
Pertuzumab (anti-HER2) 
HER2
  99.10%
CP-724714 
ErbB2, IC50: 10 nM
  98.72%
Pyrotinib dimaleate
EGFR, IC50: 13 nM
HER2, IC50: 38 nM
  98.56%
Tesevatinib
EGFR, IC50: 0.3 nM
ErbB2, IC50: 16 nM
  99.41%
Tyrphostin 23
EGFR, IC50: 35 μM (Cell Assay)
EGFR, Ki: 11 μM
   98.19%
EAI045
EGFR, IC50: 1.9 μM
EGFRL858R, IC50: 0.019 μM
EGFRT790M, IC50: 0.19 μM
EGFRL858R/T790M, IC50: 0.002 μM
   99.08%
Firmonertinib
EGFR
   99.89%
PD168393
EGFR, IC50: 0.7 nM
   98.58%
Varlitinib
HER1, IC50: 7 nM
HER2, IC50: 2 nM
 
HER4, IC50: 4 nM
98.03%
Icotinib Hydrochloride
EGFR, IC50: 5 nM
   99.89%
Lapatinib ditosylate monohydrate
EGFR, IC50: 10.8 nM
ErbB2, IC50: 9.2 nM
  99.93%
AEE788
EGFR, IC50: 2 nM
ErbB2, IC50: 6 nM
  99.13%
WZ4002
EGFRL858R, IC50: 2 nM (Cell Assay)
EGFRL858R/T790M, IC50: 8 nM (Cell Assay)
EGFRE746_A750, IC50: 3 nM (Cell Assay)
EGFRE746_A750/T790M, IC50: 2 nM (Cell Assay)
   98.99%
PD158780
EGFR, IC50: 8 μM (Cell Assay)
ErbB2, IC50: 49 nM (Cell Assay)
ErbB3, IC50: 52 nM (Cell Assay)
ErbB4, IC50: 52 nM (Cell Assay)
99.56%
Nazartinib
EGFRL858R/T790M, Ki: 31 nM
   99.03%
Lumretuzumab  
HER3
 ≥99.0%
Zipalertinib
EGFR, IC50: 1.1-8.0 nM
   99.81%
BMS-690514
EGFR, IC50: 5 nM
HER2, IC50: 20 nM
 
HER4, IC50: 60 nM
99.07%
Rezivertinib
EGFR
   99.43%
Neratinib maleate
EGFR, IC50: 92 nM
HER2, IC50: 59 nM
  99.83%
Genistein (Standard)
EGFR
   99.31%
JBJ-09-063 hydrochloride
EGFR L858R, IC50: 0.147 nM
EGFR L858R/T790M, IC50: 0.063 nM
EGFR L858R/T790M/C797S, IC50: 0.083 nM
EGFRLT/L747S, IC50: 0.396 nM
   99.37%
AG-825
EGFR, IC50: 19 μM
ErbB2, IC50: 0.35 μM
  98.02%
BI-4020
EGFRdel19 T790M C797S, IC50: 0.2 nM
EGFRdel19, IC50: 1 nM
EGFRWT, IC50: 190 nM
   99.28%
Mobocertinib succinate
EGFR exon 20 insertion
EGFR (WT)
HER2
  99.83%
TAK-285
EGFR, IC50: 23 nM
HER2, IC50: 17 nM
  99.70%
Falnidamol
EGFR, IC50: 3 nM
ErbB2, IC50: 3.4 μM
  99.41%
Bafisontamab
EGFR
   
Tuxobertinib
EGFR, Kd: 0.2 nM
HER2, Kd: 0.76 nM
  99.90%
Allitinib tosylate
EGFR, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 12 nM
ErbB2, IC50: 3 nM
 
ErbB4, IC50: 0.8 nM
99.83%
limertinib
EGFRT790M, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 0.3 nM
EGFR (WT), IC50: 6 nM
EGFRExon 19 deletion, IC50: 0.5 nM
   99.12%
WZ-3146
EGFRL858R, IC50: 2 nM
EGFRL858R/T790M, IC50: 5 nM
EGFRE746_A750, IC50: 2 nM
EGFRE746_A750/T790M, IC50: 14 nM
EGFR, IC50: 24 nM
   99.63%
Canertinib dihydrochloride
EGFR, IC50: 7.4 nM
ErbB2, IC50: 9 nM
  99.68%
Almonertinib hydrochloride
EGFRT790M, IC50: 0.37 nM
EGFRL858R/T790M, IC50: 0.29 mM
EGFRdel19 T790M, IC50: 0.214 nM
   99.77%
PD-161570
EGFR, IC50: 240 nM
   99.82%
Avitinib maleate
EGFR (WT), IC50: 7.68 nM
EGFR L858R, IC50: 0.18 nM
EGFRT790M, IC50: 0.18 nM
   99.86%
CL-387785
EGFR, IC50: 370 pM
   98.05%
Mutated EGFR-IN-1
EGFRL858R
EGFRExon 19 deletion/T790M
EGFRT790M
   99.89%
MS154
EGFR (WT), Kd: 1.8 nM
EGFRL858R, Kd: 3.8 nM
   99.42%
Piperonylic acid
EGFR
   99.91%
HKI-357
EGFR, IC50: 34 nM
ErbB2, IC50: 33 nM
  99.24%
Anbenitamab 
Human HER2
  99.22%
Myristicin
EGFR
   99.89%
VEGFR-IN-1
EGFR, IC50: 0.24 μM
   98.42%
WHI-P154
EGFR, IC50: 4 nM
   99.39%
Naquotinib
EGFR, IC50: 230 nM
   98.71%
Naquotinib mesylate
EGFRL858R/T790M
EGFRL858R
EGFRExon 19 deletion
EGFRExon 19 deletion/T790M
EGFR, IC50: 230 nM
   98.05%
Epertinib hydrochloride
EGFR, IC50: 1.48 ± 0.0 nM
HER2, IC50: 7.15 nM
 
HER4, IC50: 2.49 ± 0.1 nM
98.15%
MTX-211
EGFR
   99.81%
EGFR-IN-11
EGFRL858R/T790M/C797S, IC50: 18 nM
   99.30%
EGFR/ErbB-2/ErbB-4 inhibitor-3
ErbB1, IC50: 0.3 nM
EGFR, IC50: 2.5 nM
ErbB2, IC50: 1.1 nM
 
ErbB4, IC50: 0.5 nM
98.19%
CGP52411
EGFR, IC50: 0.3 μM
   99.82%
Allitinib
EGFR, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 12 nM
ErbB2, IC50: 3 nM
 
ErbB4, IC50: 0.8 nM
99.36%
Oritinib
EGFR (WT), IC50: 18 nM
EGFRL858R, IC50: 0.7 nM
EGFRL861Q, IC50: 4 nM
EGFRL858R/T790M, IC50: 0.1 nM
EGFRd746-750, IC50: 1.4 nM
EGFRd746-750/T790M, IC50: 0.89 nM
   99.59%
Tarlox-TKI
EGFR
   98.84%
Selatinib
EGFR, IC50: 13 nM
ErbB2, IC50: 22.5 nM
  99.83%
EGFR kinase inhibitor 3
EGFR (WT), IC50: <10 nM
EGFR L858R, IC50: 1.5 nM
EGFR L858R/T790M, IC50: 0.059 nM
EGFR L858R/T790M/C797S, IC50: 0.064 nM
   99.03%
Simotinib
EGFR, IC50: 19.9 nM
   99.39%
PF-6274484
EGFR (WT), Ki: 0.18 nM
EGFRL858R/T790M, Ki: 0.14 nM
   98.76%
BI-1622 
HER2, IC50: 7 nM
  98.97%
PD153035 Hydrochloride
EGFR, Ki: 6 pM
EGFR, IC50: 25 pM
   99.48%
EGFR-IN-12
EGFR (WT), IC50: 21 nM
EGFRL858R, IC50: 63 nM
EGFRL861Q, IC50: 4 nM
  
HER4, IC50: 7640 nM
99.40%
HG-14-10-04
EGFRLR/TM, IC50: 15.6 nM
EGFR19del/TM/CS, IC50: 22.6 nM
EGFRLR/TM/CS, IC50: 124.5 nM
   99.09%
Tarloxotinib bromide 
EGFR/HER2
  99.26%
GW2974
EGFRL858R/T790M, IC50: 0.007 μM
HER2, IC50: 0.016 μM
  99.54%
TAS0728
EGFR, IC50: 65 nM
HER2, IC50: 13 nM
 
HER4, IC50: 8.5 nM
99.71%
MS9449
EGFR (WT), Kd: 17 nM
EGFR L858R, Kd: 10 nM
   98.95%
Larotinib mesylate hydrate
EGFR (WT), IC50: 0.611 nM
EGFRL858R, IC50: 0.563 nM
EGFRL861Q, IC50: 0.423 nM
EGFRT790M, IC50: 45.2 nM
HER2, IC50: 253 nM
 
HER4, IC50: 84 nM
98.66%
JBJ-09-063 TFA
EGFR L858R, IC50: 0.147 nM
EGFR L858R/T790M, IC50: 0.063 nM
EGFR L858R/T790M/C797S, IC50: 0.083 nM
EGFRLT/L747S, IC50: 0.396 nM
   99.64%
BI-4142 
HER2, IC50: 5 nM
  98.39%
Trastuzumab rezetecan 
HER2
  98.61%
EGFR/ErbB-2/ErbB-4 inhibitor-2
EGFR, IC50: 0.017 μM
ErbB2, IC50: 0.08 μM
 
ErbB4, IC50: 1.91 μM
99.45%
AG 555
EGFR
   ≥98.0%
PD-089828
EGFR, IC50: 5.47 μM
EGFR, Ki: 3.16 μM
   98.07%
PROTAC EGFR degrader 2
EGFR, DC50: 36.51 nM
   
AV-412 free base
EGFR, IC50: 0.75 nM
EGFRL858R, IC50: 0.51 nM
EGFRL858R/T790M, IC50: 2.3 nM
EGFRT790M, IC50: 0.79 nM
ErbB2, IC50: 19 nM
  98.33%
Theliatinib
EGFR, IC50: 3 nM
EGFR, Ki: 0.05 nM
EGFR (L858R/T790M), IC50: 22 nM
   99.77%
WHI-P180
EGFR, IC50: 4 μM
   99.84%
EGFR-IN-5
EGFR, IC50: 10.4 nM
EGFRL858R, IC50: 1.1 nM
EGFRL858R/T790M, IC50: 34 nM
EGFRL858R/T790M/C797S, IC50: 7.2 nM
   99.49%
Mutant EGFR inhibitor
EGFRL858R
EGFRExon 19 deletion
EGFRT790M
   99.51%
NRC-2694
EGFR
   99.45%
CNX-2006
EGFRT790M, IC50: 20 nM
   98.42%
(Rac)-JBJ-04-125-02
EGFR (L858R/T790M), IC50: 0.26 nM
   
EGFR-IN-7
EGFR (WT), IC50: 7.92 nM
EGFR (C797S/T790M/L858R), IC50: 0.218 nM
   99.76%
EGFR-IN-17
EGFR (C797S/T790M/L858R), IC50: 0.0002 μM
   98.18%
Cinrebafusp alfa 
HER2, Kd: 0.3 nM
  98.53%
PROTAC EGFR degrader 9
EGFRL858R/T790M/C797S, DC50: 10.2 nM
EGFRL858R/T790M/C797S, Kd: 240.2 nM
EGFRdel19 T790M C797S, DC50: 36.5 nM
EGFRL858R/T790M, DC50: 88.5 nM
EGFRdel19, DC50: 75.4 nM
EGFR (WT), DC50: >300 nM
   98.35%
Lavendustin C
EGFR, IC50: 0.012 μM
   98.32%
Astragaloside VI
EGFR
   99.95%
Laprituximab emtansine
HER1
   
Tyrphostin AG 528
EGFR, IC50: 4.9 μM
ErbB2, IC50: 2.1 μM
  ≥98.0%
EGFR-IN-89
EGFR19del/TM/CS, IC50: 10.1 nM
   98.75%
AG-494
EGFR, IC50: 0.7 μM
   99.31%
RG14620
EGFR, IC50: 3 μM (Cell Assay)
   98.09%
JNJ28871063 hydrochloride
ErbB1, IC50: 22 nM
ErbB2, IC50: 38 nM
 
ErbB4, IC50: 21 nM
98.36%
EMI1
EGFRdel19 T790M C797S
EGFRL858R/T790M/C797S
   99.78%
AV-412
EGFR, IC50: 0.75 nM
EGFRL858R, IC50: 0.5 nM
EGFRT790M, IC50: 0.79 nM
EGFRL858R/T790M, IC50: 2.3 nM
ErbB2, IC50: 19 nM
  99.17%
ZD-4190
EGFR
   98.08%
PROTAC EGFR degrader 7
EGFRL858R/T790M, DC50: 13.2 nM
   99.99%
Perzebertinib 
HER2
  
Epertinib
EGFR, IC50: 1.48 ± 0.0 nM
HER2, IC50: 7.15 ± 0.5 nM
 
HER4, IC50: 2.49 ± 0.1 nM
≥98.0%
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 
HER2
  99.39%
(E)-AG 99
EGFR
   98.36%
EGFR-IN-1 hydrochloride
EGFRL858R/T790M
   
EGFR-IN-1
EGFRL858R/T790M
   
MS9427
EGFR (WT), Kd: 7.1 nM
EGFR L858R, Kd: 4.3 nM
   
JBJ-09-063
EGFR L858R, IC50: 0.147 nM
EGFR L858R/T790M, IC50: 0.063 nM
EGFR L858R/T790M/C797S, IC50: 0.083 nM
EGFRLT/L747S, IC50: 0.396 nM
   
Mutated EGFR-IN-3
EGFRL858R/T790M, IC50: 12 nM
EGFRC797S, IC50: 13 nM
   
Gozanertinib
EGFRL858R/T790M, IC50: 48 nM
EGFRWT, IC50: 15 nM
   98.37%
(S)-Sunvozertinib
EGFR exon 20 NPH, IC50: 51.2 nM
EGFR exon 20 ASV insertion, IC50: 51.9 nM
EGFRL858R/T790M, IC50: 1 nM
Her2 exon 20 YVMA insertion, IC50: 21.2 nM
  99.14%
Larotinib
EGFR (WT), IC50: 0.611 nM
EGFRL858R, IC50: 0.563 nM
EGFRL861Q, IC50: 0.423 nM
EGFRT790M, IC50: 45.2 nM
HER2, IC50: 253 nM
 
HER4, IC50: 84 nM
99.50%
SU5204 
HER2, IC50: 51.5 μM
  99.46%
Rociletinib hydrobromide
EGFRL858R/T790M, Ki: 21.5 nM
EGFRT790M, Ki: 303.3 nM
   98.04%
MJ04
EGFR, IC50: 3267 nM
   98.08%
JBJ-04-125-02
EGFR (L858R/T790M), IC50: 0.26 nM
   
pan-HER-IN-2
EGFR, IC50: 0.72 nM
EGFR (L858R/T790M), IC50: 8.2 nM
HER2, IC50: 75.1 nM
 
HER4, IC50: 2.0 nM
98.10%
EGFR/HER2-IN-9
EGFR, IC50: 3.2 nM
EGFRT790M, IC50: 8.3 nM
HER2, IC50: 14 nM
  98.73%
YS-363
EGFR, IC50: 0.96 nM
   99.52%
EGFR-IN-1 TFA
EGFRL858R/T790M
   99.38%
PKC-IN-6
EGFR, IC50: >100 μM
   99.63%
Inetetamab 
HER2
  
EGFR-IN-69
EGFR L858R/T790M/C797S, IC50: 4.3 ± 0.9 nM
EGFRL858R/T790M, IC50: 6.6 ± 0.8 nM
EGFRdel19 T790M C797S, IC50: 25.6 ± 7.5 nM
EGFRWT, IC50: 816.0 ± 82 nM
   99.58%
CHMFL-EGFR-202
EGFRT790M, IC50: 5.3 nM
EGFR, IC50: 8.3 nM
ErbB2, IC50: 8.1 nM
 
ErbB4, IC50: 3.2 nM
99.75%
T-1-PMPA
EGFRWT, IC50: 86 nM
EGFRT790M, IC50: 561.73 nM
   99.70%
ZM 449829
EGFR, pIC50: 5.0
   99.73%
SHR-A1201 
HER2
  
Nazartinib mesylate
EGFRL858R/T790M, Ki: 31 nM
   
BGB-102
EGFR, IC50: 9.6 nM
HER2, IC50: 18 nM
 
HER4, IC50: 40.3 nM
99.52%
Afatinib oxalate
EGFRL858R, IC50: 0.4 nM
EGFRWT, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
  
JBJ-02-112-05
EGFRL858R/T790M, IC50: 15 nM
   
Mobocertinib mesylate
EGFR exon 20 insertion
EGFR (WT)
HER2
  
Lapatinib tosylate
EGFR, IC50: 10.2 nM
ErbB2, IC50: 9.8 nM
  
EGFR/CSC-IN-1
EGFR, IC50: 10.52 nM
   
TX2-121-1  
HER3, IC50: 49 nM
 
Mutated EGFR-IN-2
EGFR (L858R/T790M), IC50: <1 nM
   
Oritinib mesylate
EGFR (WT), IC50: 18 nM
EGFRL858R, IC50: 0.7 nM
EGFRL861Q, IC50: 4 nM
EGFRL858R/T790M, IC50: 0.1 nM
EGFRd746-750, IC50: 1.4 nM
EGFRd746-750/T790M, IC50: 0.89 nM
   
EMI56
EGFRL858R/T790M/C797S
EGFRdel19 T790M C797S
   99.72%
EMI48
EGFRL858R/T790M/C797S
EGFRdel19 T790M C797S
   99.02%
EGFR-IN-15
EGFR, IC50: 4 nM
   
EGFR/HER2-IN-2
EGFR, IC50: 5.02 μM
HER2, IC50: 0.83 μM
  
Sacibertinib
EGFR-TK phosphorylation, EC50: 110 nM
HER2, EC50: 244 nM
  
Gancotamab 
HER2
  
SU 5402 (GMP)
EGFR, IC50: 30 nM
   
HER2-IN-5 
HER2
  
EGFR-IN-36
EGFR (WT), IC50: 19.09 nM
HER2(WT), IC50: 120.01 nM
HER2 (A775_G776insYVMA), IC50: 2.35 nM
  
EGFR/BRAF-IN-1
EGFR
   
Gamendazole 
ErbB2
  99.44%
pan-HER-IN-1
EGFR, IC50: 0.38 nM
EGFRL858R/T790M/C797S, IC50: 2.2 nM
HER2, IC50: 3.5 nM
 
HER4, IC50: 1.6 nM
COVA208 
HER2
  
BMS-599626 dihydrochloride
HER1, IC50: 20 nM
HER2, IC50: 30 nM
  
EGFR-IN-74
EGFRL858R/T790M, IC50: 138 nM
   
EGFR/HER2-IN-5
EGFR, IC50: 0.6 nM
HER2, IC50: 0.6 nM
  
JBJ-07-149
EGFRL858R/T790M, IC50: 1.1 nM
   
HER2-IN-12 
HER2, IC50: 121 nM
  
EGFR-IN-92
EGFR L858R/T790M
   
Multi-kinase-IN-4 
HER2, IC50: 0.18 mM
  
GLUT1/EGFR-IN-1
EGFR
   99.75%
Chrysophanol (Standard)
EGFR
   
EGFR/C797S-IN-1
EGFRL858R/T790M/C797S, IC50: 0.128 μM
   
PROTAC EGFR degrader 5
EGFR, DC50: 34.8 nM
   
Dual Galectin-3/EGFR-IN-1
EGFR, Kd: 3.31 μM
   
HER2-IN-8 
HER2
  
AMX-818 
HER2
  
EGFR-IN-46
EGFR, IC50: 20.17 nM
   
(E/Z)-CP-724714 
HER2
  
PDE5-IN-3
EGFR, IC50: 5.827 μM
   
EGFR WT/T790M-IN-2
EGFRT790M, IC50: 0.08 μM
EGFRWT, IC50: 0.13 μM
   
EGFR/BRAFV600E-IN-2
EGFRT790M
   
EGFR/HER2-IN-10
EGFR, IC50: 2.3 nM
HER2, IC50: 234 nM
  
EGFR-IN-60
EGFR, IC50: 0.083 μM
EGFRL858R, IC50: 0.053 μM
EGFRT790M, IC50: 0.026 μM
   
Cyclic(YCDGFYACYMDV) 
HER2
  
JGK-068S
EGFR
   
EGFR T790M/L858R-IN-4
EGFRL858R/T790M
   
EGFR-IN-62
EGFRL858R/T790M, IC50: 10 ± 1
EGFR (WT), IC50: 29 ± 2
EGFRL858R/T790M/C797S, IC50: 242 ± 9
   
EGFR-IN-52
EGFR, IC50: 0.358 μM
EGFRL858R, IC50: 86.02 μM
EGFRT790M, IC50: 432.67 μM
   
AZ14240475
EGFR exon 20 insertion
   
EGFR-IN-3
EGFRWT, IC50: 0.32 μM
   
NM-02 
HER2, EC50: 1.2 nM
  
EGFR-IN-80
EGFR, pIC50: 10.6
   
EGFR-IN-49
EGFRT790M, IC50: 65.0 nM
EGFRL858R/T790M, IC50: 13.6 nM
   
EGFR-IN-73
EGFRdel19, IC50: 119 nM
EGFRL858R, IC50: 820 nM
EGFRWT, IC50: >10 μM
EGFRL858R/T790M, IC50: >10 μM
   
GW837016X 
ErbB2
  
EGFR-IN-106
EGFR, IC50: 0.2396 μM
   
EGFR ligand-2
EGFRL858R, IC50: 21 nM
EGFRL858R/T790M, IC50: 48 nM
   
FS102 
HER2, Kd: 0.8 nM
  
EGFR-IN-124
EGFR, IC50: 0.54 μM
   
EGFR T790M/L858R-IN-2
EGFRL858R/T790M, IC50: 3.5 nM
EGFR (WT), IC50: 1290 nM
EGFRT790M, IC50: 6.7 nM
EGFRL858R, IC50: 2.1 nM
   99.66%
TAS-121
EGFR L858R, IC50: 1.7 nM
EGFR (ex19del), IC50: 2.7 nM
EGFR L858R/T790M, IC50: 0.56 nM
EGFR (ex19del/T790M), IC50: 1.1 nM
EGFR (WT), IC50: 8.2 nM
HER2, IC50: 110 nM
 
HER4, IC50: 2.6 nM
EGFR-IN-21
EGFR, IC50: 0.38 nM
   
EGFR-IN-28
EGFR
   
EGFR/COX-2-IN-1
EGFRT790M, IC50: 0.076 μM
EGFR (WT), IC50: 0.12 μM
   
EGFR/HER2/TS-IN-2
EGFR, IC50: 0.173 ± 0. μM
HER2, IC50: 0.125 ± 0. μM
  
EGFR/HER2-IN-4
EGFR, IC50: 0.6 nM
   
EGFR-IN-55
EGFRL858R/T790M, IC50: 3.9 nM
EGFRWT, IC50: 70 nM
   
EGFR-IN-116
EGFR, IC50: 0.103 μM
   
EGFR/HER2-IN-3
EGFR
HER2
  
EGFR-IN-29
EGFRT790M
   
EGFR-IN-133
EGFR (WT), IC50: 0.1 nM
   
EGFR-IN-137
EGFR, IC50: 0.192 μM
   
Emupertinib
EGFR (L858R/T790M/C797S), IC50: 0.52 nM
EGFR (d746-750/T790M/C779S), IC50: <0.3 nM
EGFR (d746-750/C797S), IC50: 0.5 nM
EGFR (WT), IC50: 0.92 nM
   
EGFR-IN-22
EGFRL858R/T790M/C797S, IC50: 0.54 nM
EGFR (WT), IC50: 4.91 nM
   
EGFR-IN-75
EGFRWT, IC50: 0.28 μM
EGFRT790M, IC50: 5.02 μM
   
RET-IN-19
EGFR, IC50: 56.78 ± 4. μM
   
DPPY
EGFR, IC50: <10 nM
   
HER2-IN-18
EGFR (WT), IC50: 500-1500 n nM
HER2(WT), IC50: <200 nM
HER2 YVMA, IC50: <200 nM
  
HSP90-IN-13
EGFR, IC50: 38.5 nM
   
HER2-IN-9 
HER2, IC50: 0.03 μM
  
EP26
EGFR, IC50: 48.6 nM
   
EGFR kinase inhibitor 1
EGFR (WT), IC50: 37 nM
EGFRL858R/T790M, IC50: 1.7 nM
EGFRL858R/T790M/C797S, IC50: >300 nM
   
EGFR-IN-56
EGFRT790M, IC50: 541.7 nM
EGFRL858R/T790M, IC50: 132.1 nM
   
HER2-IN-20
EGFR (WT), IC50: 4584 nM
HER2(WT), IC50: 49 nM
HER2 YVMA, IC50: 42 nM
  
EGFR-IN-27
EGFRdel19, IC50: <50 nM
EGFRL858R, IC50: <50 nM
EGFRL858R/T790M, IC50: <50 nM
EGFRdel19 T790M C797S, IC50: <50 nM
EGFR (C797S/T790M/L858R), IC50: <50 nM
EGFRdel19 T790M, IC50: <50 nM
   
EGFR-IN-115
EGFR, IC50: 395.2 nM
   
EGFR/VEGFR2-IN-5
EGFRT790M, IC50: 0.28 μM
   
HER2-IN-17 
Her2 exon 20 YVMA insertion, IC50: <200 nM
  
EGFR/HER2-IN-15
EGFR (WT), IC50: 37.21 nM
   
EGFR-IN-30
EGFR (WT), IC50: 1-10 nM
EGFR (L858R/T790M/C797S), IC50: <1 nM
   
HER2-IN-13
EGFR (WT), IC50: 0.40 μM
HER2, IC50: 8 nM
  
EGFR-IN-127
EGFRex19del, IC50: 136.3 nM
EGFR19del/TM/CS, IC50: 161.2 nM
   
Simotinib hydrochloride
EGFR, pIC50: 19.9 nM
   
PD 173955 analog 1
EGFR, IC50: 0.19 μM
   
EGFR/HER2/DHFR-IN-3
EGFR, IC50: 0.138 μM
HER2, IC50: 0.092 μM
  
EGFR-IN-57
EGFR, IC50: 0.054 μM
   
EGFR-IN-16
EGFR, pIC50: 4.85
HER2, pIC50: 4.74
  
EGFR-IN-109
EGFR, IC50: 25.8 nM
EGFRT790M, IC50: 182.3 nM
   
HER2-IN-15 
Her2 exon 20 YVMA insertion, IC50: <200 nM
  
EGFR-IN-67
EGFR, IC50: 0.34 μM
   
EGFR/VEGFR2-IN-3
EGFR, IC50: 0.129 μM
   
EGFR-IN-134
EGFR, IC50: 0.023 μM
   
HER2-IN-16 
Her2 exon 20 YVMA insertion, IC50: <200 nM
  
EGFR-IN-64
EGFR, IC50: 0.33 μM
   
EGFR-IN-54
EGFR, IC50: 1.623 μM
   
EGFR-IN-9
EGFR (WT), IC50: 7 nM
EGFRL858R/T790M, IC50: 28 nM
   98.84%
EGFR/HER2-IN-16
EGFR, IC50: 6.15 nM
HER1, IC50: 9.78 nM
   
EGFR/HER2/TS-IN-1
EGFR, IC50: 0.203 μM
HER2, IC50: 0.088 μM
  
HER2-IN-14
EGFR (WT), IC50: 6.3 μM
HER2, IC50: 18 nM
  
Multi-kinase-IN-6
EGFR, IC50: 0.1 μM
   
Tyrphostin 8
EGFR, IC50: 560 μM
   ≥98.0%
EGFR-IN-105 
ErbB2, : 0.68 μM
  
EGFR-IN-45
EGFR, IC50: 0.4 μM
   
2′-Thioadenosine 
ErbB2, IC50: 45 μM
  
EGFR-IN-40
EGFR, IC50: 5.3 nM
   
EGFR-IN-53
EGFR, IC50: 8.264 μM
   
EGFR-IN-51
EGFR, IC50: 0.493 μM
EGFRL858R, IC50: 102.60 μM
EGFRT790M, IC50: 461.63 μM
   
EGFR-IN-131
EGFR, IC50: 272.9 nM
   
EGFR-IN-61
EGFRL858R/T790M, IC50: 42 ± 2 nM
EGFRL858R/T790M/C797S, IC50: 137 ± 6 nM
EGFR (WT), IC50: 743 ± 20 nM
   
AG-1478 hydrochloride
EGFR, IC50: 3 nM
   
EGFR/BRAFV600E-IN-4
EGFR, IC50: 61 nM
   
EGFR kinase inhibitor 7
EGFR, IC50: 42.3 nM
   
HER2-targeted peptide H6F 
HER2
  
EGFR/VEGFR2-IN-4
EGFR, IC50: 18.7 nM
   
EGFR-IN-132
EGFR (WT), IC50: 1.6 nM
   
EGFR-IN-141
EGFR, IC50: 2.67 nM
   
EGFR-IN-120
EGFRL858R/T790M/C797S, IC50: 0.053 μM
   
EGFR-IN-159
EGFR, IC50: 29 nM
   
EGFR-IN-104
EGFRL858R/T790M, IC50: 0.33 μM
EGFRL858R/T790M/C797S, IC50: 0.133 μM
   
CDX-3379  
ErbB3
 
EGFR-IN-140
EGFR, Ki: 0.95 nM
EGFRL858R/T790M/C797S, Ki: 2.1 nM
   
EGFR T790M/L858R-IN-6
EGFR (L858R/T790M)
   
Nelipepimut-S 
HER2
  
EGFR-IN-136
EGFR (WT), IC50: 20.2 nM
EGFRLR/TM, IC50: 1.2 nM
EGFR19del/TM/CS, IC50: 2.3 nM
EGFRLR/TM/CS, IC50: 2.5 nM
   
Neptinib
EGFR (WT), IC50: 0.24 nM
EGFRL858R/T790M, IC50: 7.25 nM
EGFRL858R, IC50: 0.46 nM
EGFRT790M, IC50: 1.79 nM
   
WHI-P180 hydrochloride
EGFR, IC50: 4 μM
   
Herceptide 
HER2
  
Calotatug ginistinag 
HER2
  
Erlotinib mesylate
EGFR, IC50: 2 nM
   
SU-4313
EGFR, IC50: 11 μM
HER2, IC50: 16.9 μM
  99.31%
D-69491 hydrochloride 
HER2